{"schema_version":"secwatch.filing_event.v1","accession":"0001654954-23-010379","form_type":"8-K","ticker":"EDSA","cik":"0001540159","company_name":"Edesa Biotech, Inc.","filed_at":"2023-08-09T23:59:59+00:00","discovered_at":"2026-05-14T18:03:34.252676+00:00","generated_at":"2026-06-11T22:03:23.956028+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Edesa Biotech Q3 net loss narrows to $1.98M; paridiprubart study positive","bullets":["Net loss $1.98M ($0.10/sh) vs $5.79M ($0.37/sh) YoY; nine-month loss $6.65M ($0.34/sh) vs $14.74M ($1.04/sh).","Operating expenses fell to $2.06M from $5.80M in Q3; R&D down $3.52M to $1.03M due to lower clinical and manufacturing costs.","Cash $6.46M, working capital $5.39M at June 30, 2023; raised $4.63M YTD from share/warrant sales.","Positive university study data for paridiprubart (EB05) against respiratory pathogens; Phase 3 ARDS study ongoing.","Completed Phase 2b dermatitis study with favorable topline; planning vitiligo Phase 2 and systemic sclerosis Phase 2 studies."],"urls":{"canonical":"https://secwatch.observer/filing/0001654954-23-010379","json":"https://secwatch.observer/filing/0001654954-23-010379.json","markdown":"https://secwatch.observer/filing/0001654954-23-010379.md","text":"https://secwatch.observer/filing/0001654954-23-010379.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1540159/000165495423010379/0001654954-23-010379-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1540159/000165495423010379/edsa_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-11T22:03:23.956028+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}